THE #1 MOST USED SURFACTANT WORLDWIDE*1


CUROSURF (poractant alfa) is leading the way in global market share among US FDA-approved surfactants†1,2

*Among US FDA-approved surfactants. Number of countries used in varies for each surfactant.

†CUROSURF is available in 97 countries.2 Infasurf is available in 25 countries.3,4 Survanta data not available.


Chosen by the majority of top hospitals that use surfactant2,5-7

0255075100SHARE OF HOSPITALS (%)Top 10 Children’s HospitalsUS News and World ReportUS Member HospitalsChildren’s Hospital AssociationCUROSURF®(poractant alfa)CUROSURF®(poractant alfa)
100203040CUROSURF®(poractant alfa)200 mg/kg initial doseSurvanta®(beractant)100 mg/kg initial doseInfasurf®(calfactant)105 mg/kg initial dose||||||50 Best Hospitals for NeontologyUS News and World Report50NUMBER OF HOSPITALS

‡Based on US News and World Report’s “Best Children’s Hospitals 2020–2021: Honor Roll and Overview” and Data on file, Chiesi Farmaceutici S.p.A. and Chiesi USA, Inc., 2020.

§Based on member hospitals reporting any surfactant use or purchase that are listed in the Children’s Hospital Association’s “Children’s Hospital Directory” and Data on file, Chiesi Farmaceutici S.p.A. and Chiesi USA, Inc., 2020.

ǁBased on US News and World Report’s 50 “Best Hospitals for Neonatology” and Data on file, Chiesi Farmaceutici S.p.A. and Chiesi USA, Inc., 2020. Some hospitals may choose multiple surfactants; therefore, they may be counted more than once in the data for each surfactant.

More NICUs select CUROSURF than all other surfactants combined8-10

The most used surfactant for 10 years and counting¶1,2

(YTD)CUROSURF®(poractant alfa)200 mg/kg initial dose†Survanta®(beractant)100 mg/kg initial doseInfasurf®(calfactant)105 mg/kg initial dose020032004200520062007200820092010201120122013201420152016201720181020304050607080%%9020192020SHARE OF INFANTS TREATED (%)

The number of patients treated with each surfactant is calculated by dividing the total amount of each surfactant sold by the average amount of surfactant each patient receives. Please note that this metric only provides insight into the surfactant selected by NICUs and does not imply equivalence or superiority between or among the products for any given clinical end point.

#CUROSURF is FDA-approved for an initial dose of 200 mg/kg (2.5 mL/kg). The 100 mg/kg (1.25 mL/kg) dose of CUROSURF is approved for repeat dosing only.

Most NICUs returned to CUROSURF after trying a different surfactant**11

0255075100after 6 monthsafter 12 monthsafter 24 monthsHospitals returning to CUROSURF after trying a different surfactant%%HOSPITALS RETURNING TO CUROSURF (%)

**The number of hospitals returning to CUROSURF after trying a different surfactant is calculated by dividing the number of accounts recovered at each time point by the total number of accounts. The reason for returning to CUROSURF is unknown. Data showing values for accounts up to 24 months prior was accessed in February 2019.

CUROSURF is keeping pace with clinical practice

  • Safety and efficacy evaluated across 64 clinical trials, in over 7140 patients
  • Growing bibliography of clinical literature that includes over 99 published articles
  • The surfactant most widely studied with less invasive ventilation strategies
  • Continuing support dedicated to the advancement of neonatology research and the treatment of RDS

Want more information about CUROSURF and RDS in premature infants?

Gain quick access to multiple clinical studies and other resources all in one integrated library.

SEE RESOURCES
IMPORTANT SAFETY INFORMATION

CUROSURF® (poractant alfa) is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.

CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.

Transient adverse reactions associated with administration of CUROSURF include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.

Pulmonary hemorrhage, a known complication of premature birth and very low birth-weight, has been reported with CUROSURF. The rates of common complications of prematurity observed in a multicenter single-dose study that enrolled infants 700–2000 g birth weight with RDS requiring mechanical ventilation and FiO2 ≥ 0.60 are as follows for CUROSURF 2.5 mL/kg (200 mg/kg) (n=78) and control (n=66; no surfactant) respectively: acquired pneumonia (17% vs. 21%), acquired septicemia (14% vs. 18%), bronchopulmonary dysplasia (18% vs. 22%), intracranial hemorrhage (51% vs. 64%), patent ductus arteriosus (60% vs. 48%), pneumothorax (21% vs. 36%) and pulmonary interstitial emphysema (21% vs. 38%).

INDICATION

CUROSURF® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

Please see Full Prescribing Information.

References: 1. IQVIA Global Market Share, Total Year Q2 2020. 2. IQVIA SMART—US Edition, National Sales Perspectives, All Channels. 2020. 3. IQVIA data, 2018. 4. ONY Biotech website. http://onybiotech.com/product/infasurf/. Accessed 6/3/21. 5. US News and World Report website. https://health.usnews.com/best-hospitals/pediatric-rankings/neonatal-care. Accessed 6/3/21. 6. Children’s Hospital Association website. https://www.childrenshospitals.org/Directories/Hospital-Directory. Accessed 6/3/21. 7. US News and World Report website. https://health.usnews.com/health-news/best-childrens-hospitals/articles/best-childrens-hospitals-honor-roll-and-overview. Accessed 6/3/21. 8. IQVIA NSP CUROSURF market, February 2019. 9. Premier Research Services Surfactant Dosing Summary Average Dosing for RDS + Patients, 2013. 10. Data on file, Chiesi USA, Inc., Q2 2020. 11. Data on file, Chiesi Farmaceutici S.p.A. and Chiesi USA, Inc., 2018.